Cargando…

An integrative genome-wide transcriptome reveals that candesartan is neuroprotective and a candidate therapeutic for Alzheimer’s disease

BACKGROUND: Alzheimer’s disease is the most frequent age-related dementia, and is currently without treatment. To identify possible targets for early therapeutic intervention we focused on glutamate excitotoxicity, a major early pathogenic factor, and the effects of candesartan, an angiotensin recep...

Descripción completa

Detalles Bibliográficos
Autores principales:	Elkahloun, Abdel G., Hafko, Roman, Saavedra, Juan M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4731966/ https://www.ncbi.nlm.nih.gov/pubmed/26822027 http://dx.doi.org/10.1186/s13195-015-0167-5

Ejemplares similares

Candesartan could ameliorate the COVID-19 cytokine storm
por: Elkahloun, Abdel G., et al.
Publicado: (2020)

Candesartan in heart failure
por: Ripley, Toni L, et al.
Publicado: (2006)

Therapeutic of Candesartan and Music Therapy in Diabetic Retinopathy with Depression in Rats
por: Luo, Chengping, et al.
Publicado: (2021)

Cost Effectiveness Analysis of Candesartan Therapy in Comparison to Candesartan-Amlodipine Therapy on Hypertensive Outpatients
por: Baroroh, Faridah, et al.
Publicado: (2019)

Safety and biomarker effects of candesartan in non-hypertensive adults with prodromal Alzheimer’s disease
por: Hajjar, Ihab, et al.
Publicado: (2022)

Candesartan—the next anti-amyloid drug?
por: Yasar, Sevil
Publicado: (2022)

Candesartan induces tumor vascular normalization to improve the efficacy of radiotherapy in the therapeutic window
por: Zhu, Fei, et al.
Publicado: (2022)

Neurotrophic and Neuroprotective Actions of (−)- and (+)-Phenserine, Candidate Drugs for Alzheimer’s Disease
por: Lilja, Anna M., et al.
Publicado: (2013)

BACE2: A Promising Neuroprotective Candidate for Alzheimer’s Disease
por: Yeap, Yee Jie, et al.
Publicado: (2023)

Applying Different Techniques to Improve the Bioavailability of Candesartan Cilexetil Antihypertensive Drug
por: Aly, Usama Farghaly, et al.
Publicado: (2020)

Study of Neuroprotection by a Combination of the Biological Antioxidant (Eucalyptus Extract) and the Antihypertensive Drug Candesartan against Chronic Cerebral Ischemia in Rats
por: Trabolsi, Christine, et al.
Publicado: (2021)

Resveratrol and Neuroprotection: Impact and Its Therapeutic Potential in Alzheimer's Disease
por: Rahman, Md. Habibur, et al.
Publicado: (2020)

Brain-wide genome-wide colocalization study for integrating genetics, transcriptomics and brain morphometry in Alzheimer’s disease
por: Bao, Jingxuan, et al.
Publicado: (2023)

Candesartan cilexetil in the treatment of chronic heart failure
por: Baguet, Jean-Philippe, et al.
Publicado: (2009)

Cardio classics revisited – focus on the role of candesartan
por: De Rosa, Maria Leonarda
Publicado: (2010)

Preparation of Candesartan and Atorvastatin Nanoparticles by Solvent Evaporation (†)
por: Vaculikova, Eliska, et al.
Publicado: (2012)

Integrated transcriptomics reveals the brain and blood biomarkers in Alzheimer's disease
por: Yu, Haitao, et al.
Publicado: (2023)

Transcriptomic Analysis of Mouse Brain After Traumatic Brain Injury Reveals That the Angiotensin Receptor Blocker Candesartan Acts Through Novel Pathways
por: Attilio, Peter J., et al.
Publicado: (2021)

Formulation and Bioavailability of Novel Mucoadhesive Buccal Films for Candesartan Cilexetil in Rats
por: Mady, Omar Y., et al.
Publicado: (2021)

Commercially Available Angiotensin II At(2) Receptor Antibodies Are Nonspecific
por: Hafko, Roman, et al.
Publicado: (2013)

Correction: Commercially Available Angiotensin II AT(2) Receptor Antibodies Are Nonspecific
por: Hafko, Roman, et al.
Publicado: (2014)

Single-nucleus transcriptome analysis reveals dysregulation of angiogenic endothelial cells and neuroprotective glia in Alzheimer’s disease
por: Lau, Shun-Fat, et al.
Publicado: (2020)

Effects of adriamycin and candesartan on the collagen and elastin of the aorta in rats
por: Uhm, Jae-Sun, et al.
Publicado: (2014)

Candesartan cilexetil: COVID-19 pneumonia: case report
Publicado: (2020)

Repurposing Candesartan Cilexetil as Antibacterial Agent for MRSA Infection
por: Xu, Lanlan, et al.
Publicado: (2021)

Population Pharmacokinetics of Candesartan in Patients with Chronic Heart Failure
por: Kassem, Imad, et al.
Publicado: (2020)

Genome-wide association scan and transcriptome analysis reveal candidate genes for waterlogging tolerance in cultivated barley
por: Luan, Haiye, et al.
Publicado: (2022)

Candesartan cilexetil/hydrochlorothiazide combination treatment versus high-dose candesartan cilexetil monotherapy in patients with mild to moderate cardiovascular risk (CHILI Triple T)
por: Bönner, Gerd, et al.
Publicado: (2011)

Therapeutic Candidates for Alzheimer’s Disease: Saponins
por: Zhang, Ruifeng, et al.
Publicado: (2023)

Transcriptome-wide association study reveals candidate causal genes for lumbar spinal stenosis
por: Xu, Jiawen, et al.
Publicado: (2023)

Integration of transcriptomic and genomic data suggests candidate mechanisms for APOE4-mediated pathogenic action in Alzheimer’s disease
por: Caberlotto, Laura, et al.
Publicado: (2016)

An Integrated Genomic and Transcriptomic Analysis Reveals Candidates of Susceptibility Genes for Crohn’s Disease in Japanese Populations
por: Kakuta, Yoichi, et al.
Publicado: (2020)

Bayesian integrative analysis of epigenomic and transcriptomic data identifies Alzheimer's disease candidate genes and networks
por: Klein, Hans-Ulrich, et al.
Publicado: (2020)

Genome-Wide Association and Transcriptome Analyses Reveal Candidate Genes Underlying Yield-determining Traits in Brassica napus
por: Lu, Kun, et al.
Publicado: (2017)

Genome-wide transcriptome profile of rice hybrids with and without Oryza rufipogon introgression reveals candidate genes for yield
por: Guttikonda, Haritha, et al.
Publicado: (2020)

Flavonoids as Promising Neuroprotectants and Their Therapeutic Potential against Alzheimer's Disease
por: Minocha, Tarun, et al.
Publicado: (2022)

The Neuroprotective Effects and Therapeutic Potential of the Chalcone Cardamonin for Alzheimer’s Disease
por: Barber, Kimberly, et al.
Publicado: (2023)

Health-care costs of losartan and candesartan in the primary treatment of hypertension
por: Henriksson, M, et al.
Publicado: (2011)

Candesartan prevents impairment of recall caused by repeated stress in rats
por: Braszko, Jan Józef, et al.
Publicado: (2012)

Design and development and evaluation of candesartan cilexetil liquid filling formulations
por: Deepthi, Y., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_ofj6hfjjkqborf2cet6p432ov3